Summary
Eprosartan has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. ClinicalTrials.gov lists 1 registered trial linking Eprosartan to Chronic Kidney Disease: 1 has completed. The most advanced is Phase 1 (NCT01087749). It plans or enrolled 24 participants. Registered activity dates to 2010. The literature layer holds 2 publications for this pair: 2 clinical trial publications. Publication years run from 2004 to 2013. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Chronic Kidney Disease ranks 534 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: GFR decline averages 2-5 mL/min/year on standard care (ACE/ARB + blood pressure control); progression to end-stage renal disease (ESRD) in ~20-30% at 10 years for moderate CKD; reversal essentially impossible once structural fibrosis established.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 27.0 (trials 3.0, literature 4.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 0 other |
| Linked publications | 2 (2 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | AGTR1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01087749 | Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers 2010 | completed | Phase 1 | 24 |
Published literature
- Clinical trial publication [Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia]Kaliuzhin VV, Sibireva OF, Urazova OI et al. · Terapevticheskii arkhiv · 2013 · PMID 24261234
- Clinical trial publication Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failureNeumann J, Ligtenberg G, Oey L et al. · Journal of the American Society of Nephrology : JASN · 2004 · PMID 15504943
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Eprosartan approved for Chronic Kidney Disease?
Eprosartan has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Eprosartan in clinical trials for Chronic Kidney Disease?
ClinicalTrials.gov lists 1 registered trial linking Eprosartan to Chronic Kidney Disease: 1 has completed. The most advanced is Phase 1 (NCT01087749). It plans or enrolled 24 participants. Registered activity dates to 2010.
What does the evidence show for Eprosartan in Chronic Kidney Disease?
Eprosartan has 1 completed trial and 2 linked publications for Chronic Kidney Disease. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.